Recent News

• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
• 06.05.2025 - Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
• 05.29.2025 - Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025
• 05.29.2025 - Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025
• 05.29.2025 - Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 05.29.2025 - Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 05.13.2025 - Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
• 05.13.2025 - Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
• 05.13.2025 - Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Recent Filings

• 06.05.2025 - EX-99.1 EX-99.1
• 06.05.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 3 Initial statement of beneficial ownership of securities
• 05.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.13.2025 - 8-K Current report